AgeX CEO steps down; cash only $0.3M, substantial doubt about going concern

Serina Therapeutics, Inc.

Net loss $2.7M Q2 2023 ($0.07/sh), consistent YoY; cash $0.3M.
Juvenescence exchanged $36M debt for preferred shares in July 2023; remaining debt $1.2M.
CEO Michael West stepped down; Joanne Hackett appointed Interim CEO.
Jean-Christophe Renondin appointed to Board; possible merger with Serina mentioned.
Company expresses substantial doubt about ability to continue as going concern.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Serina Therapeutics, Inc. reported second quarter 2023 ended June 30, 2023 results: net income $2.7 million net loss attributable to AgeX for the three months ended June 30, 2023, EPS ($0.07) per share (basic and diluted).

Period: second quarter 2023 ended June 30, 2023
Net income: $2.7 million net loss attributable to AgeX for the three months ended June 30, 2023
EPS: ($0.07) per share (basic and diluted)
Result: reported results

Exact text from the filing

the net loss attributable to AgeX for the three months ended June 30, 2023 was $2.7 million, or ($0.07) per share (basic and diluted) compared to $2.6 million, or ($0.07) per share (basic and diluted), for 2022.

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

Serina Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-028506

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.